Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

179.85 +1.74 (+0.98%)
Streaming Delayed Price Updated: 11:38 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Tesla Price Target Hiked By Goldman Sachs Despite Q2 Delivery Drop: Analysts Point To ‘Meaningfully Better’ Numbers
Goldman Sachs’ new price target represents a 0.2% downside from TSLA’s closing price on Wednesday. 
Via Stocktwits
Topics Artificial Intelligence
Why Bloom Energy Stock Blasted Nearly 30% Higher Last Month
Via The Motley Fool
Topics Artificial Intelligence Energy Government
Autoliv Gets Some Wall Street Love With ‘Buy’ Call From Jefferies On Automation, Scale Upsides
The bullish call follows RBC’s recent initiation at ‘Outperform’ and comes as Autoliv maintains its 2025 margin and growth targets. 
Via Stocktwits
Topics Supply Chain
RBC Bearings’s Q1 Earnings Call: Our Top 5 Analyst Questions
RBC Bearings’ first quarter saw a positive market response despite missing Wall Street’s revenue target, as strong demand in both its aerospace and industrial segments drove year-on-year sales growth.... 
Via StockStory
Topics Earnings Economy
2 Popular AI Stocks to Sell Before They Drop 50% and 69%, According to Wall Street Analysts
Via The Motley Fool
Topics Artificial Intelligence
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network. 
Via Stocktwits
Benchmark Hikes Tesla Price Target To $475, Says EV Maker Has Advantages Over Waymo In Robotaxi Segment
The new price target represents a 45% upside to the stock’s closing price on Wednesday and follows the EV maker’s successful pilot launch of its robotaxis in Austin over the weekend. 
Via Stocktwits
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
Kratos Stock Sinks After $484M Offering Priced Below Market; Retail Traders Shrug Off Dilution
The equity raise comes as Kratos expands its role in next-gen defense systems, including a new propulsion partnership with GE Aerospace and growing investor interest driven by bullish analyst... 
Via Stocktwits
RBC Analyst Sees Growth Potential In TD Synnex Despite Short-Term Margin Pressures
RBC Capital Markets analyst David Paige reiterated an Outperform rating on TD Synnex and maintained a $145 price forecast. 
Via Benzinga
BlackBerry Stock Jumps After Wall Street Hikes Price Targets, But Remains Cautious: Retail’s Exuberant
Analysts are cautiously optimistic on BlackBerry, citing stronger pipeline visibility with QNX and IoT viewed as key growth drivers after its Q1 earnings beat estimates. 
Via Stocktwits
Topics Earnings
3 Skyrocketing Artificial Intelligence (AI) Stocks That Can Plummet 71% to 80%, According to Select Wall Street Analysts
Today's high-octane AI stocks could be some of the worst performers over the next year, based on the forecasts of select analysts. 
Via The Motley Fool
Topics Artificial Intelligence
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. 
Via Stocktwits
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. 
Via Stocktwits
CarMax Beat Expectations, But Here's What Could Still Hold It Back
RBC maintains Outperform rating on CarMax, raises price target to $81. Q1 earnings beat estimates with strong sales growth, market share gains, and cost management efforts. 
Via Benzinga
Topics Earnings
Cidara Launches 93% As A Universal Flu Shot Becomes A Closer Reality
The midstage study hit all its goals, representing a "best case" scenario, according to one analyst. 
Via Investor's Business Daily
Circle, GMS Stocks See Big Jump Friday Morning – Here’s What Wall Street Analysts Are Saying
While many analysts on Wall Street have raised their price targets on GMS after The Wall Street Journal’s report that Home Depot may have submitted a competing bid against QXO, RBC Capital said the... 
Via Stocktwits
$1000 Invested In RBC Bearings 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Should You Forget Nvidia and Buy This Artificial Intelligence (AI) Stock Right Now?
Via The Motley Fool
Topics Artificial Intelligence
Wall Street Turns Bullish On Hinge Health As Analysts Laud Profitable Growth, AI Disruption In MSK Care
Analysts noted Hinge Health’s strong return on investment, rapid automation of care delivery, and profitability milestones as key drivers of their bullish stance. 
Via Stocktwits
Topics Artificial Intelligence
RBC BEARINGS INC (NYSE:RBC) – A Quality Stock with Strong Fundamentals
RBC Bearings (NYSE:RBC) meets quality investing criteria with strong ROIC, EBIT growth, and profit quality, though its valuation remains high. A deeper look for long-term investors. 
Via Chartmill
Adobe Stock Slides as AI Optimism Reportedly Fades, But Retail Remains Defiantly Bullish
Investors are growing cautious about the timeline and payoff of Adobe’s AI initiatives, despite the company beating Q2 estimates and raising its full-year revenue forecast. 
Via Stocktwits
Topics Artificial Intelligence
Air India Crash Prompts Boeing Top Execs, Including CEO Ortberg, To Cancel Paris Air Show Visit
The Paris Air Show, which begins Monday, is the aviation industry’s largest trade show and typically sees several deals between aircraft manufacturers and airlines. 
Via Stocktwits
A Glimpse Into The Expert Outlook On RBC Bearings Through 4 Analysts
Via Benzinga
Snowflake Rival Databricks Touts Torrid Revenue Growth Rate Amid AI Boom
Snowflake stock has been pressured by views that Databricks is gaining market share as companies develop artificial intelligence applications. 
Via Investor's Business Daily
Topics Artificial Intelligence
Will the Stock Market Keep Soaring in 2025? Wall Street Analysts Are Changing Their Forecasts.
Via The Motley Fool
Topics Economy Government World Trade
What's Going On With Starbucks Stock Wednesday?
Starbucks Corporation (NASDAQ:SBUX) shares are moving higher on Wednesday. Analysts at RBC Capital and TD Securities weighed in on the stock. Here's what you need to know. 
Via Benzinga
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of... 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.